Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

Zobrazit další vydání (1)

BACKGROUND: Immunomodulatory drugs have been shown to be only modestly effective in clinically definite relapsing remitting multiple sclerosis (RRMS). It has been hypothesized that their efficacy could be higher if used at the first appearance of symptoms, that is in the clinically isolated syndrom...

Podrobná bibliografie
Hlavní autoři:	Clerico, M, Faggiano, F, Palace, J, Rice, G, Tintorè, M, Durelli, L
Médium:	Journal article
Jazyk:	English
Vydáno:	2008

Podobné jednotky

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
Autor: Clerico, M, a další
Vydáno: (2008)

Treatment for delaying conversion of the first demyelinating event to multiple sclerosis: a Cochrane review on use of recombinant interferon beta or glatiramer acetate
Autor: Clerico, M, a další
Vydáno: (2005)

Recombinant interferon-beta efficacy in preventing conversion of clinically isolated syndromes to clinically defined multiple sclerosis: a Cochrane meta-analysis
Autor: Clerico, M, a další
Vydáno: (2006)

Early treatment to prevent conversion of clinically isolated syndrome to clinically defined multiple sclerosis: a Cochrane metanalysis
Autor: Clerico, M, a další
Vydáno: (2008)

Conversion from clinically isolated syndromes to multiple sclerosis: how could we prevent it? A Cochrane review of published trials
Autor: Clerico, M, a další
Vydáno: (2007)

Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort
Autor: Valéria Coelho Santa Rita Pereira, a další
Vydáno: (2012-10-01)

Immunomodulatory treatments for preventing conversion from clinically isolated syndromes to multiple sclerosis: a Cochrane review on their efficacy
Autor: Clerico, M, a další
Vydáno: (2007)

Prevention of conversion of clinically isolated syndromes to clinically defined multiple sclerosis. Evidence from a Cochrane meta-analysis
Autor: Clerico, M, a další
Vydáno: (2008)

Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation
Autor: GJ Melendez-Torres, a další
Vydáno: (2017-09-01)

To differentiate the indication to treat the clinically isolated syndrome on the bases of different clinical onsets. The subgroup analyses from a Cochrane meta-analysis
Autor: Clerico, M, a další
Vydáno: (2009)

A Cochrane review on immunomodulatory treatments in clinically isolated syndromes at risk of converting to multiple sclerosis
Autor: Clerico, M, a další
Vydáno: (2006)

New features of glatiramer acetate for the treatment of remitting multiple sclerosis
Autor: N. Y. Lasch
Vydáno: (2015-12-01)

Pharmacoeconomic assessment of the effectiveness of glatiramer acetate (Copaxone®) in patients with multiple sclerosis
Autor: G. Ya. Shvarts
Vydáno: (2005-06-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
Autor: Özlem Taşkapılıoğlu, a další
Vydáno: (2012-03-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
Autor: Özlem Taşkapılıoğlu, a další
Vydáno: (2012-03-01)

Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
Autor: Oscar Fernández
Vydáno: (2012-08-01)

Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?
Autor: Massimiliano Mirabella, a další
Vydáno: (2022-04-01)

The influence of glatiramer acetate on Th17-immune response in multiple sclerosis.
Autor: Mikhail Melnikov, a další
Vydáno: (2020-01-01)

Nicolau syndrome following glatiramer acetate for multiple sclerosis: Case and review of reports
Autor: Methma Udawatta, a další
Vydáno: (2024-04-01)

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis
Autor: Aaron Boster, a další
Vydáno: (2011-09-01)

Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-β and glatiramer acetate for multiple sclerosis
Autor: P Tappenden, a další
Vydáno: (2004-06-01)

Can Glatiramer Acetate Prevent Cognitive Impairment by Modulating Oxidative Stress in Patients with Multiple Sclerosis?
Autor: Anna Gil-Sánchez, a další
Vydáno: (2024-04-01)

Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation
Autor: Arielle Kasindi, a další
Vydáno: (2022-05-01)

Physicochemical and Biological Examination of Two Glatiramer Acetate Products
Autor: Arthur Komlosh, a další
Vydáno: (2019-07-01)

Beneficial Effect of Melatonin Alone or in Combination with Glatiramer Acetate and Interferon β-1b on Experimental Autoimmune Encephalomyelitis
Autor: Genaro Gabriel Ortíz, a další
Vydáno: (2022-06-01)

Interleukins (IL-23 and IL-27) serum levels: Relationships with gene polymorphisms and disease patterns in multiple sclerosis patients under treatment with interferon and glatiramer acetate
Autor: Ioana S. Barac, a další
Vydáno: (2023-06-01)

GLATIRAMER ACETATE IS A FIRST-LINE DUAL-ACTION DRUG FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
Autor: T. E. Shmidt
Vydáno: (2016-12-01)

MicroRNAs Associated with Disability Progression and Clinical Activity in Multiple Sclerosis Patients Treated with Glatiramer Acetate
Autor: Ignacio Casanova, a další
Vydáno: (2023-10-01)

Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate
Autor: Justin M. Honce, a další
Vydáno: (2020-09-01)

Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue—Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers
Autor: Oliver Neuhaus, a další
Vydáno: (2021-03-01)

microRNA Expression and Its Association With Disability and Brain Atrophy in Multiple Sclerosis Patients Treated With Glatiramer Acetate
Autor: María I. Dominguez-Mozo, a další
Vydáno: (2022-06-01)

Prophylactic Glatiramer Acetate Treatment Positively Attenuates Spontaneous Opticospinal Encephalomyelitis
Autor: Ümmügülsüm Koc, a další
Vydáno: (2023-02-01)

Comparing the biological impact of glatiramer acetate with the biological impact of a generic.
Autor: Fadi Towfic, a další
Vydáno: (2014-01-01)

TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
Autor: Oreja-Guevara Celia, a další
Vydáno: (2012-09-01)

Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis
Autor: Apfel Rainer, a další
Vydáno: (2008-09-01)

Liver injury and glatiramer acetate, an uncommon association: case report and literature review
Autor: Javier Almeida, a další
Vydáno: (2017-11-01)

Beta-interferons in multiple sclerosis
Autor: Aggarwal Sourabh, a další
Vydáno: (2010-01-01)

Use of Anti-Interferon Beta Antibody Measurements in Multiple Sclerosis
Autor: Sørensen, P, a další
Vydáno: (2010)

Disease-modifying therapies and cost-of-illness progression among people newly diagnosed with multiple sclerosis: a national register-based cohort study covering treatment initiation with interferons, glatiramer acetate or natalizumab
Autor: Andrius Kavaliunas, a další
Vydáno: (2023-05-01)

Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate
Autor: Thomas F. Scott, a další
Vydáno: (2021-01-01)